[HTML][HTML] Nitrosative stress in Parkinson's disease
MG Stykel, SD Ryan - npj Parkinson's Disease, 2022 - nature.com
Parkinson's Disease (PD) is a neurodegenerative disorder characterized, in part, by the loss
of dopaminergic neurons within the nigral-striatal pathway. Multiple lines of evidence …
of dopaminergic neurons within the nigral-striatal pathway. Multiple lines of evidence …
[HTML][HTML] Lycium barbarum polysaccharide improves dopamine metabolism and symptoms in an MPTP-induced model of Parkinson's disease
J Song, L Liu, Z Li, T Mao, J Zhang, L Zhou, X Chen… - BMC medicine, 2022 - Springer
Background Parkinson's disease (PD) is the second most common neurodegenerative
disease in middle-aged and elderly populations, whereas there is no cure for PD so far …
disease in middle-aged and elderly populations, whereas there is no cure for PD so far …
7-Nitroindazole reduces L-DOPA-induced dyskinesias in non-human Parkinsonian primate
MT Herrero, JE Yuste, L Cuenca-Bermejo… - Open …, 2023 - royalsocietypublishing.org
Nitric oxide (NO) plays a pivotal role in integrating dopamine transmission in the basal
ganglia and has been implicated in the pathogenesis of Parkinson disease (PD). The …
ganglia and has been implicated in the pathogenesis of Parkinson disease (PD). The …
Caffeine Consumption and Interaction with ADORA2A, CYP1A2 and NOS1 Variants Do Not Influence Age at Onset of Machado-Joseph Disease
AC Martins, JS Pinheiro, L Szinwelski, ER Cidade… - The Cerebellum, 2024 - Springer
Background The age at onset (AO) of Machado-Joseph disease (SCA3/MJD), a disorder
due to an expanded CAG repeat (CAGexp) in ATXN3, is quite variable and the role of …
due to an expanded CAG repeat (CAGexp) in ATXN3, is quite variable and the role of …
Activation of mGlu2/3 receptors in the striatum alleviates L-DOPA-induced dyskinesia and inhibits abnormal postsynaptic molecular expression
Y Tan, C Cheng, C Zheng, W Zeng, X Yang… - Pharmacology …, 2023 - Elsevier
Group II metabotropic glutamate receptors (mGlu 2/3 receptors) have been regarded as
promising candidates for the treatment of L-DOPA-induced dyskinesia (LID); however …
promising candidates for the treatment of L-DOPA-induced dyskinesia (LID); however …
[HTML][HTML] Doxycycline to treat levodopa-induced dyskinesias in Parkinson's disease: a preliminary study
BL Santos-Lobato, MMCM Brito, ÂV Pimentel… - Arquivos de Neuro …, 2023 - SciELO Brasil
Background Levodopa-induced dyskinesia (LID) is a common motor complication of
levodopa therapy in patients with Parkinson's disease (PD). Doxycycline is a widely used …
levodopa therapy in patients with Parkinson's disease (PD). Doxycycline is a widely used …
The Impact of Pesticides on Parkinson's Disease; A Case-Control Study
A Samareh, MH Nemtollahi, HA Ebrahimi… - 2024 - researchsquare.com
Background Parkinson's disease (PD) is a complex disorder that arises from genetic and
environmental factors. The current investigation endeavors to investigate the role of …
environmental factors. The current investigation endeavors to investigate the role of …
[PDF][PDF] Lycium barbarum polysaccharide improves dopamine metabolism and symptoms in an MPTP-induced model of Parkinson's
J Song, L Liu, Z Li, T Mao, J Zhang, L Zhou… - 2022 - bmcmedicine.biomedcentral.com
Background: Parkinson's disease (PD) is the second most common neurodegenerative
disease in middle-aged and elderly populations, whereas there is no cure for PD so far …
disease in middle-aged and elderly populations, whereas there is no cure for PD so far …
Doxycycline to treat levodopa-induced dyskinesias in Parkinson's disease: A proof-of-concept study
BL Santos-Lobato, MMCM Brito, ÂV Pimentel… - medRxiv, 2022 - medrxiv.org
Background Levodopa-induced dyskinesia (LID) is a common motor complication of
levodopa therapy in patients with Parkinson's disease (PD). Doxycycline is a widely used …
levodopa therapy in patients with Parkinson's disease (PD). Doxycycline is a widely used …